Skip to main
CRMD

CorMedix (CRMD) Stock Forecast & Price Target

CorMedix (CRMD) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Cormedix is well-positioned for continued success with promising products like DefenCath and Rezzayo in its portfolio. The recent acquisition of Melinta and the potential approval of Rezafungin could drive further revenue growth. The company's focus on expansion and optimization, along with a diverse workforce, add to its potential for long-term success.

Bears say

Cormedix is heavily reliant on one product, DefenCath, for its current revenue and future growth. While DefenCath's revenue for 2026 exceeded expectations, there are potential challenges in obtaining Medicare Advantage contracting and ongoing negotiations could impact the drug's ability to exceed guidance. The company's other key product, Rezzayo, has shown positive results in clinical trials, but its potential for FDA approval in a new indication remains uncertain. Overall, Cormedix faces significant risks and dependency on a few key products, leading to a negative outlook for the company's stock.

CorMedix (CRMD) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CorMedix and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CorMedix (CRMD) Forecast

Analysts have given CorMedix (CRMD) a Buy based on their latest research and market trends.

According to 6 analysts, CorMedix (CRMD) has a Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CorMedix (CRMD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.